Proteomics analysis to reveal biological pathways and predictive proteins in the survival of high-grade serous ovarian cancer

[1]  Jun Li,et al.  A prognostic 4‐gene expression signature for squamous cell lung carcinoma , 2017, Journal of cellular physiology.

[2]  V. Adam,et al.  Amino Acid Profiling of Zinc Resistant Prostate Cancer Cell Lines: Associations With Cancer Progression , 2017, The Prostate.

[3]  A. Fernie,et al.  Integrated transcriptomic and metabolomic analysis shows that disturbances in metabolism of tumor cells contribute to poor survival of RCC patients. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[4]  P. Goodfellow,et al.  Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target , 2017, Oncogene.

[5]  Lichun Fan,et al.  MiR-203 promotes the growth and migration of ovarian cancer cells by enhancing glycolytic pathway , 2016, Tumor Biology.

[6]  Friedrich-Carl von Rundstedt,et al.  Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival , 2016, The Journal of urology.

[7]  Ronald J. Moore,et al.  Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer , 2016, Cell.

[8]  C. Ricciardelli,et al.  Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome. , 2016, Translational research : the journal of laboratory and clinical medicine.

[9]  S. Lheureux,et al.  Identification of predictive factors of response to the BH3‐mimetic molecule ABT‐737: An ex vivo experiment in human serous ovarian carcinoma , 2015, International journal of cancer.

[10]  Qing Zhao,et al.  Combining multidimensional genomic measurements for predicting cancer prognosis: observations from TCGA , 2015, Briefings Bioinform..

[11]  Satoru Miyano,et al.  Sparse Overlapping Group Lasso for Integrative Multi-Omics Analysis , 2015, J. Comput. Biol..

[12]  A. Halama.  Metabolomics in cell culture--a strategy to study crucial metabolic pathways in cancer development and the response to treatment. , 2014, Archives of biochemistry and biophysics.

[13]  G. Kenter,et al.  Development and internal validation of a prognostic model for survival after debulking surgery for epithelial ovarian cancer. , 2014, Gynecologic oncology.

[14]  A. Oberg,et al.  Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer , 2014, Cancer & Metabolism.

[15]  C. Deng,et al.  Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase. , 2014, Cancer research.

[16]  S. Lheureux,et al.  Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: An ex vivo experiment in human serous ovarian carcinoma. , 2014 .

[17]  Meeta Pradhan,et al.  Systems biology approach to stage-wise characterization of epigenetic genes in lung adenocarcinoma , 2013, BMC Systems Biology.

[18]  Yiling Lu,et al.  Predicting time to ovarian carcinoma recurrence using protein markers. , 2013, The Journal of clinical investigation.

[19]  Noah Simon,et al.  A Sparse-Group Lasso , 2013 .

[20]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[21]  N. Istfan,et al.  Fructose consumption and cancer: is there a connection? , 2012, Current opinion in endocrinology, diabetes, and obesity.

[22]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[23]  Jean-Philippe Vert,et al.  Group Lasso with Overlaps: the Latent Group Lasso approach , 2011, ArXiv.

[24]  Takashi Ishikawa,et al.  Plasma Free Amino Acid Profiling of Five Types of Cancer Patients and Its Application for Early Detection , 2011, PloS one.

[25]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[26]  R. Tibshirani,et al.  Regression shrinkage and selection via the lasso: a retrospective , 2011 .

[27]  B Rachet,et al.  Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data , 2011, Lancet.

[28]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[29]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[30]  L. Boros,et al.  Fructose induces transketolase flux to promote pancreatic cancer growth. , 2010, Cancer research.

[31]  D. Huntsman,et al.  Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[32]  E. Wagner,et al.  Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.

[33]  Y. Ishikawa,et al.  ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. , 2008, Cancer research.

[34]  Wen-li Lu,et al.  [Differentially expressed genes in adrenal gland of H22 liver cancer mice with different syndromes and in different stages]. , 2008, Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine.

[35]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[36]  Wolfgang Link,et al.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. , 2008, Current cancer drug targets.

[37]  R. Tibshirani,et al.  (37) Medications as Independent Risk Factors of Delirium in Patients With COVID-19: A Retrospective Study , 2018, Journal of the Academy of Consultation-Liaison Psychiatry.

[38]  Jian Huang,et al.  BMC Bioinformatics BioMed Central Methodology article Supervised group Lasso with applications to microarray data , 2007 .

[39]  Xianglin Shi,et al.  Constructing Molecular Classifiers for the Accurate Prognosis of Lung Adenocarcinoma , 2006, Clinical Cancer Research.

[40]  M. Yuan,et al.  Model selection and estimation in regression with grouped variables , 2006 .

[41]  W. Ichikawa.  Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway , 2006, Gastric Cancer.

[42]  Daniel E Bauer,et al.  ATP citrate lyase inhibition can suppress tumor cell growth. , 2005, Cancer cell.

[43]  C. Thompson,et al.  ATP citrate lyase is an important component of cell growth and transformation , 2005, Oncogene.

[44]  M. West,et al.  Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers , 2005, Clinical Cancer Research.

[45]  F. Hanefeld,et al.  Identification of ten novel mutations in patients with eIF2B‐related disorders , 2005, Human mutation.

[46]  B. No̸rgaard-Pedersen,et al.  Distribution of HER‐2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma , 2003, Cancer.

[47]  C. Cohen,et al.  Survivin Expression in Ovarian Carcinoma: Correlation with Apoptotic Markers and Prognosis , 2003, Modern Pathology.

[48]  R. Ozols.  Ovarian Cancer: American Cancer Society Atlas of Clinical Oncology , 2003 .

[49]  P. Bork,et al.  Bioinformatics in the post-sequence era , 2003, Nature Genetics.

[50]  F. Kern,et al.  Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells , 2001 .

[51]  F. Kern,et al.  Hyperactivation of MAPK Induces Loss of ER a Expression in Breast Cancer Cells , 2001 .

[52]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[53]  D. Cramer,et al.  A case-control study of galactose consumption and metabolism in relation to ovarian cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[54]  M. Kanehisa.  A database for post-genome analysis. , 1997, Trends in genetics : TIG.

[55]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[56]  V. Ganapathy,et al.  Constitutive expression of the taurine transporter in a human colon carcinoma cell line. , 1992, The American journal of physiology.